Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CPI inflation rose faster than expected, aligning with forecasts for higher inflation in the coming months. Check out what ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Vertex Pharmaceuticals’ stock dipped 1.73%, underperforming the S&P 500’s mild loss, despite solid monthly gains. Investors ...

Vertex Pharmaceuticals (VRTX) reached $464.2 at the closing of the latest trading day, reflecting a -1.73% change compared to its last close.

Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

Vertex struck a milestone deal with NHS England to make its cutting-edge cystic fibrosis drug ALYFTREK available to eligible ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

Investing at least part of the initial $1,000 in an artificial intelligence (AI) stock is a smart move. Despite impressive ...